London close: Equities drop after worse-than-forecast non-farms
4th Sep 2015 16:11
(ShareCast News) - Equities in the UK market ended lower on Friday after the US non-farm payrolls report missed forecasts. American employers added 173,000 jobs in August following an upwardly revised 245,000 in July, data released on Friday by the Labor Department showed. The figure was the smalle
Read moreBroker tips: Hikma Pharmaceuticals, BP, GKN
4th Sep 2015 14:00
(ShareCast News) - Goldman Sachs upgraded Hikma Pharmaceuticals to 'buy' from 'neutral', added the stock to its regional stock 'focus list' and lifted its price target to 2,840p from 2,210p. "We see the acquisition of Roxane Labs as the realisation of large transformational M&A that we had expected
Read moreFTSE 100 movers: Hikma nudges up on Goldman upgrade, miners slide
4th Sep 2015 12:06
(ShareCast News) - London's top-flight index was down 2.2% to 6,059.90 at 1515 BST, extending earlier losses following a weaker-than-expected US nonfarm payrolls report. Hikma Pharmaceuticals nudged a little higher after Goldman Sachs upgraded the stock to 'buy' from 'neutral' and lifted its price t
Read moreGoldman Sachs upgrades Hikma on Roxane Labs acquisition
4th Sep 2015 11:52
(ShareCast News) - Goldman Sachs upgraded Hikma Pharmaceuticals to 'buy' from 'neutral', added the stock to its regional stock 'focus list' and lifted its price target to 2,840p from 2,210p. "We see the acquisition of Roxane Labs as the realisation of large transformational M&A that we had expected
Read moreFTSE 100 movers: Ashtead jumps on strong interims; Glencore, BP in the red
2nd Sep 2015 13:16
(ShareCast News) - London's FTSE 100 was up 1% to 6,116 at 1423 BST in a choppy session as stocks rebounded from weakness on Tuesday. Industrial equipment rental firm Ashtead was the standout gainer after it posted better-than-expected first quarter pre-tax profits of £155m, up 23%, driven by solid
Read moreHikma Pharmaceuticals shoots higher as Barclays hails Roxane deal
2nd Sep 2015 11:57
(ShareCast News) - Hikma Pharmaceuticals got a shot in the arm on Wednesday as Barclays lifted its price target on the stock to 2,760p from 2,050p. The bank said Hikma has transformed its US exposure and long-term visibility through the $2.65bn acquisition of US specialty generics company Roxane. "
Read moreFTSE 100 movers: Glencore drags blue chips lower
19th Aug 2015 14:38
(ShareCast News) - Following the downbeat overnight sessions elsewhere, the FTSE 100 shot lower in early trade and by the afternoon had failed to crawl higher. By 1545, the blue chip index was down 1.35% at 6,438.07 points, with only a dozen companies' shares in positive territory. Leading the fall
Read moreHikma reiterates guidance as currency headwinds weigh on interims
19th Aug 2015 08:03
(ShareCast News) - Hikma Pharmaceuticals reiterated its full-year guidance, although strong currency headwinds weighed on its interim pre-tax profit. The FTSE 100 group said it expected full-year revenue to grow approximately 6% year-on-year at constant currency or around 2% at actual exchange rates
Read moreLondon close: UK equities close week lower after non-farms, BoE's 'Super Thursday'
7th Aug 2015 16:13
(ShareCast News) - A worse-than-expected US non-farm payrolls report and the Bank of England's downward revision to inflation estimates dragged UK equities lower at close of trading on Friday. The US added 215,000 jobs in July, falling short of forecasts of 225,000, according to the Labor Department
Read moreLondon open: UK stocks decline ahead of US non-farm payrolls
7th Aug 2015 08:38
(ShareCast News) - UK stocks were in the red on Friday as investors continued to process news from the Bank of England and look ahead to the all-important US non-farm payrolls report. BoE Governor Mark Carney on Thursday said the timing of a first interest rate hike was drawing closer but the exact
Read moreBroker tips: Greene King, Hikma Pharmaceuticals
29th Jul 2015 18:33
(ShareCast News) - Goldman Sachs reinstated its 'buy' rating on Greene King with a 1,060p price target, saying it expects the company to deliver consistent earnings growth given its exposure to accelerating UK consumer discretionary spending, execution of synergies post its Spirit acquisition and in
Read moreFTSE 100 movers: GSK and Hikma lead blue chips higher
29th Jul 2015 15:24
(ShareCast News) - The FTSE 100 index built an early lead on Wednesday and stayed in positive territory thanks to forecast-busting results from several heavyweights in the pharma, tobacco and banking sectors. London's blue chip index was up 0.57% to 6,592.54 at 1435 BST. Top of the leaderboard mid-
Read moreJefferies ups Hikma to 'buy', says Roxane deal is a "game changer"
29th Jul 2015 11:44
(ShareCast News) - Hikma Pharmaceuticals got a boost after Jefferies upgraded the stock to 'buy' from 'hold' and raised its price target to 2,615p from 2,134p as it integrates the company's "transformational" deal with Roxane Laboratories. "In our view Hikma is transitioning to a period of remarkabl
Read moreLondon close: Investors play it safe ahead of Fed meeting
28th Jul 2015 17:56
(ShareCast News) - The selling pressure let up ahead of the start of a two-day policy meeting from the US Federal Reserve, with some investors braced in case the post-meeting statement sprang any surprises. The FTSE 100 finished the session higher by 0.77% to the 6,555.28 mark, alongside a similar b
Read moreFTSE 100 movers: RSA rockets, Hikma higher
28th Jul 2015 14:35
(ShareCast News) - London's primary index was holding onto its gain by mid-afternoon on Tuesday, boosted by deals and deal talk. At 1415 BST, the FTSE 100 was up 0.81% to 6,557.62, with only a dozen of the blue chip constituents in the red. As soon as markets opened, RSA Insurance moved to the top
Read more